Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 2 1

Status

Recruiting 2Completed 2Unknown 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 5

Conditions

Nasopharyngeal Carcinoma 39Carcinoma, Non-Small-Cell Lung 30Esophageal Squamous Cell Carcinoma 22Carcinoma, Hepatocellular 21Triple Negative Breast Neoplasms 18Squamous Cell Carcinoma of Head and Neck 17Breast Neoplasms 17Advanced Solid Tumor 17Stomach Neoplasms 14Melanoma 14Small Cell Lung Carcinoma 13Colorectal Neoplasms 13Uterine Cervical Neoplasms 12Neoplasms 10Carcinoma, Transitional Cell 10Carcinoma, Renal Cell 10Recurrence 9Solid Tumor 7Sarcoma 7Neoplasm Metastasis 7Liver Neoplasms 7Head and Neck Neoplasms 7Urinary Bladder Neoplasms 5Rectal Neoplasms 5Esophageal Neoplasms 5Advanced Solid Tumors 5Pancreatic Neoplasms 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4Cholangiocarcinoma 4

Interventions

Injections 27Carboplatin 18Docetaxel 14pembrolizumab 13Paclitaxel 12Bevacizumab 10durvalumab 8Nivolumab 8Cisplatin 8Fluorouracil 7Pemetrexed 6Oxaliplatin 6Leucovorin 6trifluridine tipiracil drug combination 5toripalimab 5tislelizumab 5linifanib 5Capecitabine 5zimberelimab 4talazoparib 4olaparib 4fludarabine 4Panobinostat 4Itraconazole 4Irinotecan 4Gemcitabine 4Everolimus 4tremelimumab 3sotorasib 3sintilimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Advanced Solid Tumors × toripalimab × Clear all
NCT06832982 2026-04-09

Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002

Shanghai Pushi Medical Science Co. Ltd

Phase 1 Recruiting
66 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT06208410 2025-07-25

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors

Risen (Suzhou) Pharma Tech Co., Ltd.

Phase 1/2 Recruiting
306 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT04169672 2023-03-02

Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors

Hutchmed

Phase 2 Completed
248 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT04481009 2022-12-12

A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors

Eucure (Beijing) Biopharma Co., Ltd

Phase 1/2 Completed
26 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT05502393 2022-08-16

A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors

Shanghai Junshi Bioscience Co., Ltd.

Phase 1 Unknown
118 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡